Age-related iFR/FFR discordance: does it matter?

William F. Fearon^{1,2*}, MD

1. Division of Cardiovascular Medicine and Cardiovascular Institute, Stanford University, Stanford, CA, USA; 2. VA Palo Alto Health Care System, Palo Alto, CA, USA

The relationship between microvascular dysfunction and fractional flow reserve (FFR) has long been recognised¹. Microvascular dysfunction results in a lower maximal achievable flow down a coronary artery, a lower pressure gradient and a higher FFR across a given stenosis. Some have argued that this represents an underappreciation by FFR of the functional significance of a stenosis. However, De Bruyne and colleagues demonstrated that, in the presence of microvascular dysfunction resulting from a remote myocardial infarction, FFR remained accurate for detecting lesions responsible for myocardial ischaemia¹. The higher FFR which occurs in the setting of microvascular dysfunction is not falsely high, but simply reflects the lower potential gain in maximal myocardial flow should one relieve the epicardial stenosis.

The impact of ageing on FFR was first demonstrated by Lim and colleagues in a substudy of the FAME trial, in which the investigators found that, across a given stenosis severity, FFR was significantly higher in older patients compared with younger ones, and the proportion of functionally significant lesions was significantly lower². The effect of age on discordance between FFR and non-hyperaemic pressure ratios (NHPR) such as the instantaneous wave-free ratio (iFR) has also been investigated. Derimay and colleagues found that younger patients were significantly more likely to have a positive FFR and negative iFR, while older patients were more likely to have the reverse³.

In this issue of EuroIntervention, Faria and colleagues report on their performance of a *post hoc* analysis of 690 coronary pressure wire recordings in 591 patients in which they compared the correlation between iFR and FFR and evaluated the subjects' hyperaemic response to adenosine based on patient age⁴.

Article, see page 757

They divided the subjects into tertiles based on age and found that, for a given stenosis, the youngest group (33-58 years old) was more likely to have a positive FFR and negative iFR compared with the two older groups (those 59-69 years old or >70 years old). There was a trend towards more cases of a positive iFR in the setting of negative FFR as patients became older. The hyperaemic response to adenosine, defined as the difference between the resting pressure ratio and FFR, decreased significantly with patient age. Finally, FFR correlated with age, while iFR did not. The authors conclude that the vasodilatory response of the microcirculation to adenosine declines with age, leading to an increase in FFR, while iFR does not appear to be affected.

**Corresponding author: Stanford University School of Medicine, 300 Pasteur Drive, H2103, Stanford, CA 94305, USA. E-mail: wfearon@stanford.edu*

This is an interesting study which adds important data to the literature regarding the impact of age on coronary physiologic indices. The strengths of this study include the large number of subjects, measurement of both iFR and FFR, and the demonstration of reduced hyperaemia in older subjects. These findings need to be considered in context. Stenosis severity correlated with age, with younger patients in this study having significantly more severe stenoses based on angiography, which may have contributed to the change in FFR observed, although the investigators mention controlling for lesion severity in their analyses. It is also possible that other age-related processes, such as the significantly higher systolic blood pressure seen in the older cohort, could have contributed to increased microvascular dysfunction. The most important limitation of this study is the lack of clinical outcome data.

A key question raised by this study is whether a low FFR in a younger patient with a high iFR is falsely low due to some sort of supraphysiologic hyperaemia, as has been previously suggested. However, the DEFINE-FLOW trial by Johnson and colleagues would argue otherwise⁵. They found that patients with an abnormal FFR and preserved coronary flow reserve (CFR) had a significantly higher target vessel failure rate with medical therapy alone compared with patients with normal FFR and normal CFR. Moreover, in the FAME 2 trial which compared percutaneous coronary intervention (PCI) with medical therapy in patients with at least one lesion with an abnormal FFR the investigators found similarly high adverse event rates in medically treated patients younger than 60 years old compared with those over age 60 at five-year follow-up, arguing that FFR is not falsely positive in young patients⁶.

Another key unanswered question is whether a high FFR in an older patient with a low iFR is a falsely high FFR leading to misdiagnosis of a lesion responsible for ischaemia. As mentioned by the investigators, the FAME 1 trial comparing angiography-guided PCI with FFR-guided PCI found similar benefit in older patients, arguing against missed significant lesions². Another study developing an index to predict events in lesions deferred based on FFR found that younger age, not older age, was a significant predictor of adverse outcomes, further supporting the argument that FFR is not misdiagnosing older patients⁷. Finally, registry data from Ahn and colleagues⁸ including 6,468 deferred lesions in patients with an average age of 64 (identical to the current study) found that age was not an independent predictor of outcomes, while FFR was, further supporting the validity of FFR in both younger and older patients.

Answering the above questions with future study will hopefully determine the clinical significance, if any, of the iFR/FFR discordance associated with age.

Conflict of interest statement

W. Fearon reports institutional research support from Abbott Vascular, Boston Scientific and Medtronic; consulting with Cath-Works and minor stock options with HeartFlow.

References

1. De Bruyne B, Pijls NH, Bartunek J, Kulecki K, Bech JW, De Winter H, Van Crombrugge P, Heyndrickx GR, Wijns W. Fractional flow reserve in patients with prior myocardial infarction. *Circulation*. 2001;104:157-62.

2. Lim HS, Tonino PA, De Bruyne B, Yong AS, Lee BK, Pijls NH, Fearon WF. The impact of age on fractional flow reserve-guided percutaneous coronary intervention: a FAME (Fractional Flow Reserve versus Angiography for Multivessel Evaluation) trial substudy. *Int J Cardiol.* 2014;177:66-70.

3. Dérimay F, Johnson NP, Zimmermann FM, Adjedj J, Witt N, Hennigan B, Koo BK, Barbato E, Esposito G, Trimarco B, Rioufol G, Park SJ, Baptista SB, Chrysant GS, Leone AM, Jeremias A, Berry C, De Bruyne B, Oldroyd KG, Pijls NHJ, Fearon WF. Predictive factors of discordance between the instantaneous wave-free ratio and fractional flow reserve. *Catheter Cardiovasc Interv.* 2019;94:356-63.

4. Faria DC, Lee JM, van der Hoef T, Mejia-Renteria H, Echavarria-Pinto M, Baptista SB, Cerrato E, Garcia-Garcia H, Davies J, Onuma Y, Samady H, Piek JJ, Serruys PW, Lerman A, Escaned J. Age and functional relevance of coronary stenosis: a post hoc analysis of the ADVISE II trial. *EuroIntervention*. 2021;17:757-64.

5. Johnson NP, Matsuo H, Nakayama M, Eftekhari A, Kakuta T, Tanaka N, Christiansen EH, Kirkeeide RL, Gould KL. Combined Pressure and Flow Measurements to Guide Treatment of Coronary Stenoses. *JACC Cardiovasc Interv.* 2021;14:1904-13.

6. Xaplanteris P, Fournier S, Pijls NHJ, Fearon WF, Barbato E, Tonino PAL, Engstrøm T, Kääb S, Dambrink JH, Rioufol G, Toth GG, Piroth Z, Witt N, Fröbert O, Kala P, Linke A, Jagic N, Mates M, Mavromatis K, Samady H, Irimpen A, Oldroyd K, Campo G, Rothenbühler M, Jüni P, De Bruyne B; FAME 2 Investigators. Five-Year Outcomes with PCI Guided by Fractional Flow Reserve. *N Engl J Med.* 2018;379:250-9.

7. Depta JP, Patel JS, Novak E, Gage BF, Masrani SK, Raymer D, Facey G, Patel Y, Zajarias A, Lasala JM, Amin AP, Kurz HI, Singh J, Bach RG. Risk model for estimating the 1-year risk of deferred lesion intervention following deferred revascularization after fractional flow reserve assessment. *Eur Heart J.* 2015;36:509-15.

8. Ahn JM, Park DW, Shin ES, Koo BK, Nam CW, Doh JH, Kim JH, Chae IH, Yoon JH, Her SH, Seung KB, Chung WY, Yoo SY, Lee JB, Choi SW, Park K, Hong TJ, Lee SY, Han M, Lee PH, Kang SJ, Lee SW, Kim YH, Lee CW, Park SW, Park SJ; IRIS-FFR Investigators†. Fractional Flow Reserve and Cardiac Events in Coronary Artery Disease: Data From a Prospective IRIS-FFR Registry (Interventional Cardiology Research Incooperation Society Fractional Flow Reserve). *Circulation*. 2017;135: 2241-51.